Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pro, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pro, B.

Novel Agents in Peripheral T-cell Lymphomas

Barbara Pro, MD

From the M.D. Anderson Cancer Center, Houston, TX

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Supported by Allos Therapeutics and Gloucester Pharmaceuticals.

Address reprint requests to Barbara Pro, MD, Associate Professor of Medicine, Department of Lymphoma/Myeloma, Unit 429, the University of Texas MD Anderson Cancer Center,1515 Holcombe Blvd, Houston, TX 77030; e-mail: bpro{at}mdanderson.org

Overview: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of disorders with poor response to conventional chemotherapy and associated, in most cases, with a dismal prognosis. There is no consensus on the best treatment strategy for patients with relapsed/refractory disease. Attempts to adapt treatment regimens commonly used for B-cell lymphomas to PTCLs have yielded disappointing results. A better understanding of the pathogenesis of these diseases has resulted in the identification of new targets for treatment. Several new and promising therapeutic options have emerged within the past few years and will be discussed in this review.